Jonathan M Holmes1, Ruth E Manny2, Elizabeth L Lazar3, Eileen E Birch4, Krista R Kelly4, Allison I Summers5, Stacy R Martinson6, Aparna Raghuram7, Jeffrey D Colburn8, Christine Law9, Justin D Marsh10, Derek P Bitner11, Raymond T Kraker3, David K Wallace12. 1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. Electronic address: pedig@jaeb.org. 2. University of Houston College of Optometry, Houston, Texas. 3. Jaeb Center for Health Research, Tampa, Florida. 4. Retina Foundation of the Southwest, Dallas, Texas. 5. Casey Eye Institute, Oregon Health & Science University, Portland, Oregon. 6. Virginia Pediatric Eye Center, Virginia Beach, Virginia. 7. Boston Children's Hospital, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts. 8. Spokane Eye Clinic, Spokane, Washington. 9. Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada. 10. Children's Mercy Hospitals and Clinics, Kansas City, Missouri. 11. Wolfe Eye Clinic, West Des Moines, Iowa. 12. Department of Ophthalmology, Indiana University, Indianapolis, Indiana.
Abstract
PURPOSE: To compare visual acuity (VA) improvement in children aged 7 to 12 years with amblyopia treated with abinocular iPad game plus continued spectacle correction vs. continued spectacle correction alone. DESIGN: Multicenter randomized clinical trial. PARTICIPANTS: One hundred thirty-eight participants aged 7 to 12 years with amblyopia (33-72 letters, i.e., approximately 20/200 to 20/40) resulting from strabismus, anisometropia, or both. Participants were required to have at least 16 weeks of optical treatment in spectacles if needed or demonstrate no improvement in amblyopic-eye visual acuity (VA) for at least 8 weeks prior to enrollment. METHODS:Eligible participants (mean age 9.6 years, mean baseline VA of 59.6 letters, history of prior amblyopia treatment other than spectacles in 96%) were randomly assigned to treatment for 8 weeks with the dichoptic binocular Dig Rush iPad game (prescribed for 1 hour per day 5 days per week) plus spectacle wear if needed (n = 69) or continued spectacle correction alone if needed (n = 69). MAIN OUTCOME MEASURES: Change in amblyopic-eye VA from baseline to 4 weeks, assessed by a masked examiner. RESULTS: At 4 weeks, mean amblyopic-eye VA letter score improved from baseline by 1.3 (2-sided 95% confidence interval [CI]: 0.1-2.6; 0.026 logMAR) with binocular treatment and by 1.7 (2-sided 95% CI: 0.4-3.0; 0.034 logMAR) with continued spectacle correction alone. After adjusment for baseline VA, the letter score difference between groups (binocular minus control) was -0.3 (95% CI: -2.2 to 1.5, P = 0.71, difference of -0.006 logMAR). No difference in letter scores was observed between groups when the analysis was repeated after 8 weeks of treatment (adjusted mean: -0.1, 98.3% CI: -2.4 to 2.1). For the binocular group, adherence data from the iPad indicated that slightly more than half of the participants (58% and 56%) completed >75% of prescribed treatment by the 4- and 8-week visits, respectively. CONCLUSIONS: In children aged 7 to 12 years who have received previous treatment for amblyopia other than spectacles, there was no benefit to VA or stereoacuity from 4 or 8 weeks of treatment with the dichoptic binocular Dig Rush iPad game.
RCT Entities:
PURPOSE: To compare visual acuity (VA) improvement in children aged 7 to 12 years with amblyopia treated with a binocular iPad game plus continued spectacle correction vs. continued spectacle correction alone. DESIGN: Multicenter randomized clinical trial. PARTICIPANTS: One hundred thirty-eight participants aged 7 to 12 years with amblyopia (33-72 letters, i.e., approximately 20/200 to 20/40) resulting from strabismus, anisometropia, or both. Participants were required to have at least 16 weeks of optical treatment in spectacles if needed or demonstrate no improvement in amblyopic-eye visual acuity (VA) for at least 8 weeks prior to enrollment. METHODS: Eligible participants (mean age 9.6 years, mean baseline VA of 59.6 letters, history of prior amblyopia treatment other than spectacles in 96%) were randomly assigned to treatment for 8 weeks with the dichoptic binocular Dig Rush iPad game (prescribed for 1 hour per day 5 days per week) plus spectacle wear if needed (n = 69) or continued spectacle correction alone if needed (n = 69). MAIN OUTCOME MEASURES: Change in amblyopic-eye VA from baseline to 4 weeks, assessed by a masked examiner. RESULTS: At 4 weeks, mean amblyopic-eye VA letter score improved from baseline by 1.3 (2-sided 95% confidence interval [CI]: 0.1-2.6; 0.026 logMAR) with binocular treatment and by 1.7 (2-sided 95% CI: 0.4-3.0; 0.034 logMAR) with continued spectacle correction alone. After adjusment for baseline VA, the letter score difference between groups (binocular minus control) was -0.3 (95% CI: -2.2 to 1.5, P = 0.71, difference of -0.006 logMAR). No difference in letter scores was observed between groups when the analysis was repeated after 8 weeks of treatment (adjusted mean: -0.1, 98.3% CI: -2.4 to 2.1). For the binocular group, adherence data from the iPad indicated that slightly more than half of the participants (58% and 56%) completed >75% of prescribed treatment by the 4- and 8-week visits, respectively. CONCLUSIONS: In children aged 7 to 12 years who have received previous treatment for amblyopia other than spectacles, there was no benefit to VA or stereoacuity from 4 or 8 weeks of treatment with the dichoptic binocular Dig Rush iPad game.
Authors: Susan A Cotter; Allison R Edwards; David K Wallace; Roy W Beck; Robert W Arnold; William F Astle; Carmen N Barnhardt; Eileen E Birch; Sean P Donahue; Donald F Everett; Joost Felius; Jonathan M Holmes; Raymond T Kraker; Michele Melia; Michael X Repka; Nicholas A Sala; David I Silbert; Katherine K Weise Journal: Ophthalmology Date: 2006-06 Impact factor: 12.079
Authors: Tina Y Gao; Cindy X Guo; Raiju J Babu; Joanna M Black; William R Bobier; Arijit Chakraborty; Shuan Dai; Robert F Hess; Michelle Jenkins; Yannan Jiang; Lisa S Kearns; Lionel Kowal; Carly S Y Lam; Peter C K Pang; Varsha Parag; Roberto Pieri; Rajkumar Nallour Raveendren; Jayshree South; Sandra Elfride Staffieri; Angela Wadham; Natalie Walker; Benjamin Thompson Journal: JAMA Ophthalmol Date: 2018-02-01 Impact factor: 7.389
Authors: Jonathan M Holmes; Elizabeth L Lazar; B Michele Melia; William F Astle; Linda R Dagi; Sean P Donahue; Marcela G Frazier; Richard W Hertle; Michael X Repka; Graham E Quinn; Katherine K Weise Journal: Arch Ophthalmol Date: 2011-07-11
Authors: Mitchell M Scheiman; Richard W Hertle; Roy W Beck; Allison R Edwards; Eileen Birch; Susan A Cotter; Earl R Crouch; Oscar A Cruz; Bradley V Davitt; Sean Donahue; Jonathan M Holmes; Don W Lyon; Michael X Repka; Nicholas A Sala; David I Silbert; Donny W Suh; Susanna M Tamkins Journal: Arch Ophthalmol Date: 2005-04
Authors: Roy W Beck; Pamela S Moke; Andrew H Turpin; Frederick L Ferris; John Paul SanGiovanni; Chris A Johnson; Eileen E Birch; Danielle L Chandler; Terry A Cox; R Clifford Blair; Raymond T Kraker Journal: Am J Ophthalmol Date: 2003-02 Impact factor: 5.258
Authors: Jonathan M Holmes; Vivian M Manh; Elizabeth L Lazar; Roy W Beck; Eileen E Birch; Raymond T Kraker; Eric R Crouch; S Ayse Erzurum; Nausheen Khuddus; Allison I Summers; David K Wallace Journal: JAMA Ophthalmol Date: 2016-12-01 Impact factor: 7.389
Authors: Krista R Kelly; Reed M Jost; Lori Dao; Cynthia L Beauchamp; Joel N Leffler; Eileen E Birch Journal: JAMA Ophthalmol Date: 2016-12-01 Impact factor: 7.389
Authors: Eileen E Birch; Reed M Jost; Angie De La Cruz; Krista R Kelly; Cynthia L Beauchamp; Lori Dao; David Stager; Joel N Leffler Journal: J AAPOS Date: 2019-05-16 Impact factor: 1.220
Authors: Ruth E Manny; Jonathan M Holmes; Raymond T Kraker; Zhuokai Li; Amy L Waters; Krista R Kelly; Lingkun Kong; Earl R Crouch; Ingryd J Lorenzana; Maan S Alkharashi; Jennifer A Galvin; Melissa L Rice; B Michele Melia; Susan A Cotter Journal: Optom Vis Sci Date: 2022-03-01 Impact factor: 1.973
Authors: Reed M Jost; Krista R Kelly; Jeffrey S Hunter; David R Stager; Becky Luu; Joel N Leffler; Lori Dao; Cynthia L Beauchamp; Eileen E Birch Journal: J AAPOS Date: 2020-10-09 Impact factor: 1.220